Did MSM distract Americans on Obama’s real role with one of the companies responsible for H1N1

Is the Obama administration counting on a United Nations-touted H1N1 pandemic to wipe out Town Hall resistance to Obamacare? U.S. officials admit they expect millions of new cases of the H1N1 flu this winter, as the dreaded flu season arrives in the Northern Hemisphere. The fear of a pandemic spread of the virus is already a clear and present danger in killing off any hope of a possible economic recovery late this year or early next. If H1N1 can grind economic recovery to a halt, why can’t it send Obamacare off in a totally new direction?

---

Are rumors that the flu scare will pave the way for martial law based on more reality than conspiracy? Was Laszlo Consulting managing director George Laszlo, who wrote “How Will Obama HIT Biopharm?” on Jan. 20, 2009 seeing into a crystal ball, or was he just lucky? Reminiscing about New Year’s Eve in Times Square “everyone is wishing that things will go better in 2009,” Laszlo opined, “And so do we in the Biopharm industry where many are not sure if the new guy in the White House is friend or foe. This is especially so in the United States, a country where free market capitalism is fiercely defended and anything that smacks of socialism is treated with great suspicion." Listed among eight reasons Laszlo gave for why “nothing will happen fast” on what could be expected from Obama on the Healthcare Information Technology (HIT) front was number 5: “The population at large gets a chance to make comments and participate in hearings.” (Emphasis CFP’s). Stepping back in time to 9:42 a.m., March 7, 2007 White House hopeful Barack Obama was preparing for a press conference in the Capitol. “The freshman Illinois Democrat and Rep. Luis Gutierrez (D-Ill) skedded the newser to tout a bill to freeze immigration fees bringing in the leaders of Latino empowerment groups concerned about the plight of immigrants. (Lynn Sweet, Chicago Sun-Times). “However, this event, designed to introduce legislation Gutierrez and Obama have been working on for months, will be overshadowed by a page one story in the New York Times questioning the credibility of Obama’s blind trust. Turns out Obama bought stock in little known companies whose investors included some of his major donors. Said ABC of the Times story: “In their front page investigative must-read, Mike McIntire and Christopher Drew of the New York Times report: “Less than two months after ascending to the United States Senate, Barack Obama bought more than $50,000 worth of stock in two speculative companies whose major investors included some of his biggest political donors.” One of those two companies was AVI BioPharma, a biotech company that was then starting to develop a drug to treat avian flu, now in the race to save the world from H1N1. (CFP is dismissing the second company Skyterra Obama invested in because this is a story about Obama in relationship to H1N1). In any case, the Obama campaign soon told the New York Times: “There is no evidence that any of (Obama’s) actions ended up benefiting either company during the roughly eight months that he owned the stocks. “(Obama) sold them at a net loss of $13,000”. Nothing mentioned though in the many teachable moments about pandemics in the eight-month period. Back to Obama and flu bugs. It was Obama and eight cosponsors who introduced the avian flu bill (S. 969) on April 28, 2005. According to ABC, “Bipartisan Senate Amendment Cosponsored by Obama Did Not Earmark Funds for Particular Companies. The bipartisan Harkin amendment, which Obama cosponsored, provided $3.8 billion related to the flu and included funding for new drug development. However, it did not direct funds to individual companies. (SA 2283, 109th Congress; introduced 10/26/05). “Amendment passed by Full Senate Had No Positive Impact on Avi BioPharma Stock. “Money Avi BioPharma Received Was Unconnected to Obama Or Avian flu. In October 2005, AVI BioPharma preliminarily announced DoD funding for research on four viruses. That funding was unconnected to Obama and was not related to research on avian flu. U.S. Senate Committee on Appropriations has approved $22 million for AVI’s research and development programs as part of the FY2006 defense spending bill...the spending bill would direct $22 million to AVI for the continued development of technology to test for and find therapeutic agents for Ebola ($6 million) viruses, and anthrax and ricin toxins ($4 million), In addition, the allocation includes new funding for an AVI project to test for and find therapeutic agents for dengue virus ($6 million).” AVI BioPharma eventually received $11 million in the DoD Appropriations Bill for 2006 (thestreet.com, AVI BioPharma Press release, 10/3/05). The clock is now ticking out the year 2009. In 2007, Obama called a push to increase federal financing to fight avian flu “one of my top priorities since arriving in the Senate”. In 2009, the worry is now about a global pandemic courtesy of Avian flu’s cousin H1N1. Since touting the March 2007 New York Times $50,000 Obama portfolio story, ABC has since morphed into what some describe as the `All Barack Channel’. The New York Times ran Obama’s Health Care op-ed only on Sunday. Did the ABC and New York Times lead the masses on a paper chase about Obama not making much money on the AVI BioPharma investment to distract John Q. Public from the more important issue: the influence Obama may have gleaned from his association with Big Pharm? Meanwhile, it may be more than your Granny you have to hide from Barack Hussein Obama and Co.